More topics

Limited coverage drugs – certolizumab

Last updated on October 24, 2022

Generic name

 certolizumab

Strength

 200 mg/mL
Form subcutaneous injection solution

Special Authority criteria

Approval period
Ankylosing spondylitis

For the treatment of Ankylosing Spondylitis when prescribed by a rheumatologist AND when prescribed according to established criteria (as indicated on the Special Authority form below).

First approval: 1 year

Renewal: 1 year or indefinite
Psoriatic arthritis

For the treatment of psoriatic arthritis when prescribed by a rheumatologist AND when prescribed according to established criteria (as indicated on the Special Authority form below).

First approval: 1 year

Renewal: 1 year or indefinite
Rheumatoid arthritis

For the treatment of rheumatoid arthritis when prescribed by a rheumatologist AND when prescribed according to established criteria (as indicated on the relevant Special Authority form below). 

First approval: 1 year

Renewal: 1 year or indefinite

Practitioner exemptions

  • None

Special notes

  • None

Special Authority requests